Figures S5 and S6 shows that the risk of ALT elevation (RR: 1.58, 95% CI: 1.26–1.99) and AST elevation (RR: 1.56, 95% CI: 1.22–2.00) were significantly increased. What’s more, PD-1/PD-L1 inhibitors were associated with higher risk of hepatitis (RR: 3.54, 95% CI: 1.96–6.38), as is shown in Figure S7. Finally, as to endocrine disorders, the adverse event of treatment on endocrine is mainly thyroid dysfunction. Figure S8 shows that the hypothyroid of using PD-1 or PD-L1 was 5.29 (95% CI: 4.00–6.99) times compared with that of control group. Here, CD274 is linked to Hepatitis.